Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 2Myeloid 1

Conditions

Myelodysplastic Syndromes 1Hematologic Diseases 1Bone Marrow Neoplasms 1Bone Marrow Diseases 1

Interventions

fludarabine phosphate 140Cyclophosphamide 132Busulfan 102Peripheral Blood Stem Cell Transplantation 95Imatinib Mesylate 94Mycophenolic Acid 91Cytarabine 82Azacitidine 80Tacrolimus 79Cyclosporine 78Whole-Body Irradiation 77fludarabine 74Antilymphocyte Serum 71Methotrexate 65Filgrastim 63nilotinib 59Melphalan 51Decitabine 50Radiotherapy 43Dasatinib 34Granulocyte Colony-Stimulating Factor 33ruxolitinib 31Clofarabine 31Etoposide 30thymoglobulin 29Thiotepa 29Cord Blood Stem Cell Transplantation 28sargramostim 27Methylprednisolone 26Stem Cell Transplantation 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × SCIO-469 × Myeloid × Clear all
NCT00113893 2013-11-07

SCIO-469: Open-Label Study for Patients With Myelodysplastic Syndromes.

Scios, Inc.

Phase 2 Completed
62 enrolled
Myeloid

Bone Marrow Diseases, Hematologic Diseases, Myelodysplastic Syndromes, Bone Marrow Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡